Prosensa Holding NV (NASDAQ:RNA) on May 20 reported financial results for the first quarter ending March 31, 2014 and provided an update on the next steps for its exon-skipping platform for the treatment of Duchenne Muscular Dystrophy (DMD). Revenue for the three months ended March 31, 2014 was EURO14.8 million, compared with EURO2.4 million in 2013. Prosensa Holding NV (NASDAQ:RNA) weekly performance is 37.87%. On last trading day company shares ended up $8.41. Prosensa Holding NV (NASDAQ:RNA) distance from 50-day simple moving average (SMA50) is 37.02%.
Neuralstem, Inc. (NYSEMKT:CUR) announced that data from the NSI-189 Phase Ib study in major depressive disorder (MDD) will be presented at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Florida, on June 17th at 4:15 EDT. Neuralstem, Inc. (NYSEMKT:CUR) shares advanced 0.52% in last trading session and ended the day on $3.86. CUR return on assets is -117.40%.Neuralstem, Inc. (NYSEMKT:CUR) quarterly performance is 6.63%.
Stock analysts at Canaccord Genuity decreased their target price on shares of EnteroMedics (NASDAQ:ETRM) from $6.00 to $4.00 in a report issued on Thursday, AnalystRatingsNetwork reports. Canaccord Genuity’s target price would suggest a potential upside of 112.77% from the stock’s previous close. EnteroMedics Inc. (NASDAQ:ETRM) shares moved up 3.80% in last trading session and was closed at $1.91, while trading in range of $1.77 – $1.93. EnteroMedics Inc. (NASDAQ:ETRM) year to date (YTD) performance is -6.37%.
On May 8, 2014, BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued a press release to announce the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 with the U.S. Securities and Exchange Commission and to provide a review of the Company’s recent achievements and an update on business operations and upcoming milestones for 2014. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) ended the last trading day at $9.33. Company weekly volatility is calculated as 5.99% and price to cash ratio as 5.13.BioDelivery Sciences International, Inc. (NASDAQ:BDSI) showed a positive weekly performance of 7.36%.
Vical Incorporated (NASDAQ:VICL) on 6 may posted a loss of 4 cents per share in the first quarter of 2014, narrower than the Zacks Consensus Estimate of a loss of 6 cents per share and the year-ago loss of 11 cents per share. On last trading day company shares ended up $1.23. Analysts mean target price for the company is $3.23. Vical Incorporated (NASDAQ:VICL) distance from 50-day simple moving average (SMA50) is -1.76%.